Katelyn is a reporter with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

The set also lands at No. 5 on the overall Billboard 200. By Keith Caulfield Paul McCartney’s latest studio album, The Boys of Dungeon Lane, debuts in the top five on six Billboard charts (dated June ...

Zackari Greif is a List Writer at DualShockers who has been covering games professionally since 2021. A lifelong gamer and former writer for GameRant and Fix Gaming Channel, Zackari has written across ...

Roll20 wants you to make more dungeons. And with a hot new update to Dungeon Scrawl, now you can make ’em fast in real time. Roll20 announced a new update for Dungeon Scrawl, a real-time ...

Roll20 has unveiled a new free tool for Dungeons & Dragons players, as well as GMs of any fantasy title, as they have created the free Dungeon Generator. This is not AI or some poorly designed program ...

We've all been in a D&D session where the party has barrelled off the main path and into a cave or mine or crypt, despite the dungeon master's unsubtle hints that they've got absolutely nothing ...

AI has taken the world by storm over the last few years, with millions of users writing prompts on platforms like ChatGPT to generate content, images, and yes videos. Still, some of these platforms ...

If you’ve ever played a role-playing game (RPG), you know how fun it is to create your character in any way you choose and embark on epic adventures. Now, picture an AI-powered, text-based RPG where ...

Hasbro’s Wizards of the Coast is putting their trademarked D back in DM-ing with the launch of a new “Dungeons & Dragons” actual-play TV series. Launching with its first two episodes available on ...

The live-action “Dungeon Crawler Carl” TV series is now officially in development at Peacock, Variety has learned. Based on the LitRPG book series of the same name by Matt Dinniman, the project was ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...